Ranibizumab Biosimilar – Research Grade [ICH4031]

ichorbio’s Ranibizumab Biosimilar – Research Grade is manufactured in a cGMP compliant facility. ichorbio: the best antibodies for in vivo research.

ichorbio’s research grade ranibizumab biosimilar is available in the following sizes:
5mg, 10mg, 20mg, 50mg, 100mg
ichorbio regularly manufactures bulk multi-gram amounts of our ranibizumab biosimilar – please contact us for pricing.

VEGF-A

n/a

IgG1 kappa

Vascular endothelial growth factor A, VPF, Vascular Permeability Factor

Humanized

Human

Detects human VEGF. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Ranibizumab. ichorbio’s ranibizumab biosimilar is for research use only (RUO).

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by CHO expression system.

1.0 – 5.0 mg/ml

Sterile, colorless to pale yellow solution containing histidine hydrochloride, 10% trehalose dihydrate and Tween 20. pH 5.5. BSA and Azide free.

>95% by SDS-PAGE and HPLC

≤ 0.75 EU/mg as determined by the LAL method

Ranibizumab Biosimilar – Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

Functional Assays

Each investigator should determine their own optimal working dilution for specific applications.